Available Until 1/31/2023

Intensive Studies for Recertification: Pharmacotherapy (Cert # L229093)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 01/04/2022
Content Release Date: 02/02/2022
Expiration Date: 01/31/2023
Activity Type: Application-based
CE Credits: 6.5 (BPS and ACPE) contact hours
Activity Fee: $100 (ASHP member); $150 (non-member)

Activity Overview

The Intensive Study Package is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). Using a case-based approach, the activities provide high-level, interactive discussions on contemporary and emerging issues in pharmacotherapy. 

The Pharmacotherapy Intensive Study Recertification Package consists of 4 activities (see table below) and provides up to 6.5 contact hours of continuing pharmacy education and/or recertification credit.   

These activities are part of the ASHP professional development program for BCPS recertification approved by the BPS.  For pharmacists who maintain more than one certification, three of the activities are approved for multiple specialties (see table below).

These activities were presented as part of the 2021 Virtual Midyear Clinical Meeting. Learners who claimed ACPE credit for these activities as part of that meeting, should not claim ACPE credit again.

 

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:

  • Treatment and Prevention of HIV
  • Fluid Resuscitation in Septic Shock
  • 2020 Antimicrobial Resistant Gram-Negative Infection Treatment Guidelines
  • Diuretic Resistance in AHF

Board certified pharmacists are eligible to receive up to 6.5 contact hours of recertification credit for completing this package. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Activity

ACPE Number

Contact Hours (ACPE & BPS)

Recertification Assessment

Long Acting Antiretroviral Therapy for the Treatment and Prevention of HIV Infection (BCPS)

0204-0000-21-315-H02-P

1.50

73%

Fluid Resuscitation Controversies in Adult and Pediatric Septic Shock – Does One Size Fit All? (BCPS, BCCCP, BCPPS)

0204-0000-21-246-H01-P

1.50

73%

Beyond the Top Line: A Point-Counterpoint Discussion of the 2020 Antimicrobial Resistant Gram-Negative Infection Treatment Guideline (BCPS, BCCCP)

0204-0000-21-269-H01-P 2.00

66%

Resistance is Futile: Overcoming Diuretic Resistance in Acute Heart Failure (BCPS, BCCCP)

0204-0000-21-305-H01-P

1.50

66%

Long Acting Antiretroviral Therapy for the Treatment and Prevention of HIV Infection
0204-0000-21-315-H02-P
At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Describe the pharmacology and pharmacokinetics of cabotegravir and rilpivirine as long-acting injectable antiretroviral therapy agents.
  • Apply clinical trial data and the principles of antiretroviral therapy to determine appropriate candidates for long-acting cabotegravir and rilpivirine for HIV treatment.
  • Apply clinical trial data and the principles of HIV pre-exposure prophylaxis to determine appropriate candidates for long-acting cabotegravir for HIV prevention.
  • Recommend strategies for solving drug therapy related problems common to long-acting antiretroviral agents including missed doses, adverse drug reactions and drug-drug interactions.

This activity is approved for Board Certified Pharmacotherapy Specialist (BCPS) recertification credit. 

Fluid Resuscitation Controversies in Adult and Pediatric Septic Shock – Does One Size Fit All?
0204-0000-21-246-H01-P
At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Analyze recommendations for the initial fluid bolus dose for adult patients with septic shock.
  • Select an appropriate fluid bolus dose for a pediatric patient with septic shock.
  • Recommend the most appropriate type of fluid for an adult or pediatric patient with septic shock.
  • Evaluate strategies for assessing fluid responsiveness in adults.
  • Recognize criteria for reassessment of fluid management in children.

This activity is approved for Board Certified Critical Care Pharmacist (BCCCP), Board Certified Pediatric Pharmacy Specialist (BCPPS), and Board Certified Pharmacotherapy Specialist (BCPS) recertification credit. 

Beyond the Top Line: A Point-Counterpoint Discussion of the 2020 Antimicrobial Resistant Gram-Negative Infection Treatment Guideline
0204-0000-21-269-H01-P

At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Discuss broad-spectrum agents that are included in the 2020 gram-negative treatment guidelines.
  • Recommend evidence-based therapies for antibiotic-resistant gram-negative infections.
  • Assess clinical scenarios in which guideline non-preferred therapy may be considered.

This activity is approved for Board Certified Critical Care Pharmacist (BCCCP) and Board Certified Pharmacotherapy Specialist (BCPS) recertification credit.

Resistance is Futile: Overcoming Diuretic Resistance in Acute Heart Failure
0204-0000-21-305-H01-P
At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Given a patient failing to meet diuresis goals, identify etiologies of diuretic resistance and evidence-based strategies for management.
  • Given a patient presenting with acute decompensated heart failure (ADHF) and volume overload, recommend an individualized strategy for relieving congestive symptoms using evidence-based literature.
  • Given a patient failing to meet diuresis goals, apply literature to design a modified strategy for relieving congestive symptoms.

This activity is approved for Board Certified Critical Care Pharmacist (BCCCP) and Board Certified Pharmacotherapy Specialist (BCPS) recertification credit.

Faculty bios

Monique R. Bidell, Pharm.D., BCPS
Clinical Pharmacy Specialist – Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts 

Jennifer Cocohoba, Pharm.D., AAHIVP, BCPS
Professor, Department of Clinical Pharmacy
University of California San Francisco School of Pharmacy
Pharmacist, UCSF Womens’ HIV Program 

Zachary L. Cox, Pharm.D., FHFSA
Associate Professor
Lipscomb University College of Pharmacy
Nashville, Tennessee 

Stormi E. Gale, Pharm.D., BCCP
Clinical Pharmacist – Cardiology Subject Matter Expert
Novant Health Matthews Medical Center
Baltimore, Maryland 

Ronak G. Gandhi, Pharm.D., BCPS
Attending Clinical Pharmacist- Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts 

Pete Johnson, Pharm.D., BCPS, BCPPS, FPPA, FCCM, FASHP
Professor—University of Oklahoma College of Pharmacy
CICU Pediatric Clinical Specialist—Oklahoma Children’s Hospital at OU Health
Oklahoma City, Oklahoma 

Thomas P. Lodise, Pharm.D., PhD
Professor, Pharmacy Practice
Albany College of Pharmacy and Health Sciences
Albany, New York 

Jason Schafer, Pharm.D., M.P.H., AAHIVP, BCIDP, BCPS, FASHP
Vice Chair and Professor, Department of Pharmacy Practice
Jefferson College of Pharmacy
Philadelphia, Pennsylvanie 

Elizabeth Sherman, Pharm.D., AAHIVP
Associate Professor, Department of Pharmacy Practice
Nova Southeastern University College of Pharmacy
Clinical Pharmacy Specialist, Memorial Healthcare System
Fort Lauderdale, Florida 

Heather Torbic, Pharm.D., BCPS, BCCCP
Medical ICU Clinical Specialist—Cleveland Clinic
Cleveland, Ohio

*Content Matter Experts

Christopher Betz, Pharm.D., BCPS, FASHP, FKSHP*
Snehal Bhatt, Pharm.D., BCPS-AQ Cardiology, FASHP, AACC*
Angela Bingham, Pharm.D., BCPS, BCNSP, BCCCP
Holly L.Byrnes, Pharm D., BCPS
Susan R. Dombrowski, M.S., R.Ph.
Mary M. Hess, Pharm.D., FASHP, FCCM, FCCP, BCCCP
Kristi Hofer, Pharm.D.
Douglas Slain, Pharm.D., B.S.Pharm., BCPS, AQ-ID*
Paul M. Szumita, Pharm.D., BCCCP, BCPS, FASHP, FCCM
Jennifer Thackray, Pharm.D., BCPPS, BCPS

Hakeem Abayomi, B.S., Pharm.D., BCPS, BCPPS, BCIDP
Karen Abboud, Pharm.D., BCPS
Shannon Allcron, Pharm.D., BCCCP, BCPS
John Austin, Pharm.D., BCPS, BCCCP
Catherine Bobea, Pharm.D., BCPS
Lindsey Branstetter, Pharm.D., BCCCP
Quintin Broussard, Pharm.D., BCPS, BCCCP, BCNSP
Judah Brown, Pharm.D., BCCCP
Paul Bush, Pharm.D., MBA, BCPS, FASHP
J. Spencer Dingman, Pharm.D.
Brady Diveley, Pharm.D., BCPS, BCCCP
Roxana Dumitru, Pharm.D., BCPS, BCCCP
Karly Erickson, Pharm.D., BCPS, BCCCP
Adonia Eskandari, Pharm.D., BCCCP
Sonia Everhart, Pharm.D., BCPS, BCCCP, FCCM
Brittany Faley, Pharm.D., BCPS
Stefanie Forman, Pharm.D.
Renee Fraatz, Pharm.D., BCPS
Hailey Freeman, Pharm.D., BCPS
Michael Ganio, Pharm.D., M.S., BCPS, BCSCP, FASHP
Brianne Hansen, Pharm.D., BCPS, BCCCP
Nicholas Hunt, Pharm.D., BCCCP
Lisa Infanti, Pharm.D., BCCCP
Thomas Johnson, Pharm.D., MBA, BCPS, BCCCP, FASHP, FACHE, FCCM
Maureen Jones, Pharm.D., BCCCP
Bailey Kernan, Pharm.D., BCPS
Dalton Kuebel, Pharm.D., BCCCP
Biljana Lanier, BS.Pharm., BCPPS
Bayli Larson, Pharm.D., MS, BCPS
Thomas Laudone, Pharm.D., BCPPS
Tracey Le, Pharm.D., BCCCP
Rebecca Lee, Pharm.D.
Dustin Linn, Pharm.D., BCPS, BCCCP
Susan Lowrie, Pharm.D., BCGP, BCPS
Melanie Madorsky, Pharm.D., BCPS, BCCP, BCCCP
Eric Maroyka, Pharm.D., BCPS
Michael McQuade, Pharm.D., BCCCP, BCPS
Haley Morrissey, Pharm.D., BCCCP
Oussayma Moukhachen, Pharm.D., BCPS, BCCCP
Anna Niedzwiecki, Pharm.D., BCPS, BCCCP
Daniel Padgett, Pharm.D., BCPS, BCCCP
Christi Parker, Pharm.D., BCPS, BCCCP
Kajal K Patel, Pharm.D., BCPS, BCCCP
Madalyn Pearson, Pharm.D., BCPS, BCGP
Caitlin Pfaff, Pharm.D., BCPS, BCCCP
Nicole Rudawsky, Pharm.D., BCPS
Beth Sawrey, Pharm.D., BCPPS
Hanady Sharabash, BCCP
Laurie Sherrick, Pharm.D., BCCCP
Anna Simmont, Pharm.D., BCPS, BCPPS
Bridger Singer, Pharm.D., BCPS, BCCCP
Melanie Sisco, Pharm.D., BCPS, BCCCP
Brian Spoelhof, Pharm.D., BCPS, BCCCP
Alexi Spoto, Pharm.D., BCPS
Andrew Stevens, Pharm.D., BCPS
Maria Stubbs, BS.Pharm., BCPS-AQ Cardiology, BCCCP
MaKayla Swanson, Pharm.D., BCPS
Latisha Tomlinson, Pharm.D., BCPS, BCCCP
Steve Tran, Pharm.D., BCPS, BCPPS
Shelby Warring, Pharm.D., BCPPS
Leanna Winnick, Pharm.D., BCPS
Michael Wright, Pharm.D., BCPS, BCCCP
Adena Yau, Pharm.D., BCPS, PhC
Cathy Young, Pharm.D., BCPS, NCPS

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Jennifer Cocohoba: ViiV: grant/research support
  • Elizabeth Sherman: Merck: grant/research support
  • Jason Schafer: Merck: advisory committee/board member, grant/research support; ViiV: advisory board
  • Thomas Lodise: Melinta Therapeutics: Advisory Board, Consultant, Speaker's Bureau; Merck: Consultant, Grant Recipient; Shionogi: Advisory Board, Consultant, Speaker's Bureau; Spero Therapeutics: Advisory Board, Consultant 

All other planners, presenters, reviewers, and ASHP staff and others with an opportunity to control content report no financial relationships relevant to this activity.

Activities which can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations.  Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

These activities were developed by ASHP.